SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.

SA-CCRC-球孢子菌病治疗方法和疫苗的开发。

• 批准号: 10541225
• 负责人: CHIUNG-YU HUNG
• 金额: $ 135.7万
• 依托单位: UNIVERSITY OF TEXAS SAN ANTONIO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10541225
• 关键词: Address; Affect; Antibiotic Resistance; Antifungal Agents; Area; Arizona; Azole resistance; Basic Science; Bioinformatics; California; Cells; Clinical; Clinical Research; Coccidioides; Coccidioides immitis; Coccidioides posadasii; Coccidioidomycosis; Communities; Data; Development; Disease Outcome; Drug Screening; Ensure; Evaluation; Funding; Genomics; Geographic Locations; Goals; Health; Health Care Costs; Immunity; Immunocompromised Host; Immunotherapeutic agent; Immunotherapy; In Vitro; Individual; Infection; Infrastructure; Institution; Investigator-Initiated Research; Knowledge; Libraries; Lung; Medical; Mentors; Messenger RNA; Modeling; Morbidity - disease rate; Mycoses; Office of Administrative Management; Persons; Pharmaceutical Preparations; Predisposition; Prevention; Research; Research Personnel; Research Project Grants; Resources; Risk; Scientist; Site; Southwestern United States; Structure; Talents; Technical Expertise; Techniques; Technology; Testing; The science of Mycology; Therapeutic; Time; Training; Translational Research; Treatment outcome; United States; Vaccines; career development; clinically significant; desert fever; design; drug development; experience; high throughput screening; improved; in vivo; industry partner; instrumentation; member; new technology; next generation; novel; operation; programs; research and development; therapeutic development; translational pipeline; vector-based vaccine

Summary (Overall) San Antonio has a rich tradition of excellence in the field of Medical Mycology, including Coccidioidomycosis, also referred to as Valley Fever. These infections affect hundreds of thousands of healthy and immunocompromised individuals in the endemic areas of the arid Southwest U.S., with a majority of cases in California and Arizona. There are very few drugs to treat these infections and no vaccine is available. Growing levels of antibiotic resistance are a major concern, and the latest data on the expansion of the geographical area of infection is very worrisome. To address these major shortcomings, we propose the establishment of the San Antonio-based Coccidioidomycosis Collaborative Research Center (SA-CCRC). The new Center will be a highly collaborative place for synergistic multi- and interdisciplinary interactions by members of the Center, which include highly experienced investigators in the field of Coccidioides research, as well as others with substantial knowledge and/or technical expertise in other areas whose talents are being attracted to this field for the very first time. Overall, the SA-CCRC creates an optimal cohesive infrastructure to support integrated research, leverages resources at each of the participating sites and organizations, and also extends to the establishment of novel academic- industrial partnerships. Our Center has a strong translational emphasis, being distinctively focused on the development of antifungal drugs and vaccines against coccidioidomycosis. The center is anchored by an administrative core which will serve a central hub for providing the necessary organizational, administrative and financial oversight structure for the Center’s day-to-day operations. The overall objectives for the SA- CCRC are: i) to advance basic, translational and clinical research in the field of Coccidioidomycosis via investigator-driven research projects, ii) to adapt, develop and implement state of the art techniques to the Coccidioidomycosis field of research in support of the three different projects and the coccidioidomycosis community at large, and iii) to administer a Development and Research Program for pilot funding and mentoring of junior investigators and those new to the field of coccidioidomycosis. Altogether, the proposed SA-CCRC program will fill critical voids and will have a powerful and sustainable effect on the field of coccidioidomycosis research.

摘要（总体） 圣安东尼奥在医学真菌学领域拥有丰富的卓越传统，包括 球虫菌病，也称为山谷热。这些感染会影响数十万 在美国西南地区的地方性地区，健康，免疫受损的人， 加利福尼亚和亚利桑那州的大多数案件。几乎没有药物可以治疗这些感染，没有 可疫苗可用。抗生素抗性的水平不断提高，这是一个主要问题，有关的最新数据 感染地理区域的扩展非常糟糕。为了解决这些主要缺点， 我们提出建立基于圣安东尼奥的球菌病的合作研究 中心（SA-CCRC）。新中心将成为协同多和的高度协作场所 该中心成员的跨学科互动，其中包括经验丰富的研究人员 球虫研究领域以及具有丰富知识和/或技术专长的其他人 在其他领域，他们的才能第一次吸引了这一领域。总体而言，SA-CCRC 创建一个最佳的凝聚力基础架构来支持综合研究，利用每个 参与的站点和组织，还扩展到建立新颖的学术 - 工业伙伴关系。我们的中心具有很强的翻译重点，明确地集中在 开发针对球虫菌病的抗真菌药物和疫苗。中心由 行政核心将为中心枢纽提供必要的组织，行政管理 和中心日常运营的财务监督结构。 SA-的总体目标 CCRC是：i）在球虫菌病领域的基本，翻译和临床研究通过 研究人员驱动的研究项目，ii）适应，开发和实施艺术技术的状态 球虫菌病领域的研究领域支持三个不同的项目和球虫菌病 整个社区，以及iii）管理试点资金的开发和研究计划， 对初级研究人员和球虫病领域的新研究人员的指导。总共提议 SA-CCRC计划将填补关键空隙，并将对领域产生强大而可持续的影响 球虫病术研究。